Escalating Beyond Corticosteroids in Ocular and Lower-Burden MG

In this episode, ‘Escalating Beyond Corticosteroids in Ocular and Lower-Burden MG,’ the panel of neuromuscular experts explores how clinicians decide when conventional treatment is no longer sufficient. Faculty discuss corticosteroids primarily as a bridge rather than an ideal long-term strategy, with an emphasis on reducing chronic exposure while another therapy becomes effective. For some patients, conventional steroid-sparing immunosuppression can provide excellent control, but its slower onset means prolonged dependence on corticosteroids may be required.

The panel describes circumstances that can support earlier escalation to a targeted therapy. Patients who remain functionally limited despite corticosteroids, require higher steroid doses, or need more rapid restoration of daily activities may warrant a different approach rather than prolonged therapeutic waiting. Faculty distinguish patients recovering from myasthenic crisis or exacerbation from those with more gradually evolving disease, noting that each situation creates different levels of urgency and different bridging needs.

Importantly, the discussion challenges the assumption that apparently mild MG necessarily produces a low disease burden. Ocular symptoms, subtle weakness, or relatively low MG-ADL scores can still prevent a patient from driving, working, teaching, or performing highly specialized tasks. The panel stresses that functional consequences should therefore be considered alongside conventional severity measures when deciding whether treatment escalation is appropriate. The central message is that therapy should reflect what symptoms actually prevent the patient from doing, not solely how severe those symptoms appear on paper.

The next episode in this series, ‘How Antibody Status Guides Targeted Therapy Selection in MG,’ features the panelists examining how antibody status, comorbidities, prior response, reproductive considerations, and treatment logistics influence the choice among FcRn, complement, and B-cell–directed therapies.